Biotech Companies Set To Profit From Animal-Organ Transplants

SIDEBAR: Alternate Paths to Xenotransplantation The tantalizing possibility of using a potentially unlimited supply of organs from animals to replace damaged human ones -- through xenotransplantation -- has, in just the past few years, jumped the divide from purely academic possibility to big-business likelihood. A half-dozen or so well-supported biotechnology companies have sprung into existence to pursue the creation of transgenic animals -- pigs with human genes, primarily -- or to develop

Franklin Hoke
Oct 15, 1995

SIDEBAR: Alternate Paths to Xenotransplantation

The tantalizing possibility of using a potentially unlimited supply of organs from animals to replace damaged human ones -- through xenotransplantation -- has, in just the past few years, jumped the divide from purely academic possibility to big-business likelihood. A half-dozen or so well-supported biotechnology companies have sprung into existence to pursue the creation of transgenic animals -- pigs with human genes, primarily -- or to develop novel antirejection strategies to support animal-organ transplants. The goal is to alleviate a desperate and growing shortage of human organs available for transplantation.

Stephen Squinto BIG BUSINESS: About 100,000 patients annually could use xenografts, says Alexion's Stephen P. Squinto.


However, the emergence of this new industry has sparked sharp opposition from animal-rights advocates, who call the move poor science, poor medicine, and an unethical exploitation of nonhuman species. They and other critics also fear that the rush to...

Interested in reading more?

The Scientist ARCHIVED CONTENT

ACCESS MORE THAN 30,000 ARTICLES ACROSS MANY TOPICS AND DISCIPLINES

Become a Member of

Receive full access to more than 35 years of archived stories, digital editions of The Scientist Magazine, and much more!
Already a member?